



February 2011

Prednisolone Modified Release Tablet (Lodotra®▼) for the treatment of moderate to severe, active rheumatoid arthritis

The Interface Prescribing and New Therapies Subgroup (IPNTS) discussed the above drug at a meeting on the 23rd February 2011. The recommendation of this subgroup is as follows:*

The Interface Prescribing & New Therapies Subgroup of the GMMMG considered the use of Lodotra® for the treatment of moderate to severe, active rheumatoid arthritis (RA) in adults, particularly when accompanied by early morning stiffness

The group does not recommend the use of Lodotra®

Trial data was short term (12 weeks) and placebo controlled (or used an active comparator that isn't available in the UK).

More cost effective treatment options are currently available.

One years supply of Lodotra® 1mg/2mg/5mg MR tablet would cost ~£325 compared to ~£13 for prednisolone 5mg tablets¹

According to set criteria Lodotra® was deemed to be a low priority for funding

¹prices correct at time of publication

Review date: July 2018

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.